If you remember anyone who used to say that biotech would never amount to anything, now's the time to make the told-you-so phone call. Biogen Idec says it is considering a possible sale of the company, and one of the interested parties is Carl Icahn, who offered at least $23 billion, according to this article in the Wall Street Journal. Biogen Idec has a market cap of about $23.5 billion.

 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.